skip to main content
Language:
Refined by: Journal Title: Investigational New Drugs remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Material Type:
Article 		Add to e-Shelf

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Shapiro, Geoffrey I. ; LoRusso, Patricia ; Kwak, Eunice ; Pandya, Susan ; Rudin, Charles M. ; Kurkjian, Carla ; Cleary, James M. ; Pilat, Mary Jo ; Jones, Suzanne ; de Crespigny, Alex ; Fredrickson, Jill ; Musib, Luna ; Yan, Yibing ; Wongchenko, Matthew ; Hsieh, Hsin-Ju ; Gates, Mary R. ; Chan, Iris T. ; Bendell, Johanna

Investigational new drugs, 2020-04, Vol.38 (2), p.419-432 [Peer Reviewed Journal]

New York: Springer US

Full text available

Citations Cited by
2
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Material Type:
Article 		Add to e-Shelf

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

Shapiro, Geoffrey I. ; LoRusso, Patricia ; Cho, Daniel C. ; Musib, Luna ; Yan, Yibing ; Wongchenko, Matthew ; Chang, Ilsung ; Patel, Premal ; Chan, Iris T. ; Sanabria-Bohorquez, Sandra ; Meng, Raymond D. ; Bendell, Johanna C.

Investigational new drugs, 2021-02, Vol.39 (1), p.163-174 [Peer Reviewed Journal]

New York: Springer US

Full text available

Citations Cited by
3
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
Material Type:
Article 		Add to e-Shelf

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors

Jones, Suzanne F. ; Siu, Lillian L. ; Bendell, Johanna C. ; Cleary, James M. ; Razak, Albiruni R. A. ; Infante, Jeffrey R. ; Pandya, Shuchi S. ; Bedard, Philippe L. ; Pierce, Kristen J. ; Houk, Brett ; Roberts, W. Gregory ; Shreeve, S. Martin ; Shapiro, Geoffrey I.

Investigational new drugs, 2015-10, Vol.33 (5), p.1100-1107 [Peer Reviewed Journal]

New York: Springer US

Full text available

Citations Cited by
4
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
Material Type:
Article 		Add to e-Shelf

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Rodon, Jordi ; Braña, Irene ; Siu, Lillian L ; De Jonge, Maja J ; Homji, Natasha ; Mills, David ; Di Tomaso, Emmanuelle ; Sarr, Celine ; Trandafir, Lucia ; Massacesi, Cristian ; Eskens, Ferry ; Bendell, Johanna C

Investigational new drugs, 2014-08, Vol.32 (4), p.670-681 [Peer Reviewed Journal]

New York: Springer US

Full text available

Citations Cited by
5
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
Material Type:
Article 		Add to e-Shelf

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

Bendell, Johanna C. ; Kurkjian, Carla ; Infante, Jeffrey R. ; Bauer, Todd M. ; Burris, Howard A. ; Greco, F. Anthony ; Shih, Kent C. ; Thompson, Dana S. ; Lane, Cassie M. ; Finney, Lindsey H. ; Jones, Suzanne F.

Investigational new drugs, 2015-04, Vol.33 (2), p.463-471 [Peer Reviewed Journal]

Boston: Springer US

Full text available

Citations Cited by

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

  • Implemented by: ABCD-USP USP   Social Network Logos: Freepik

Searching Remote Databases, Please Wait

  • Searching for
  • inscope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
  • Show me what you have so far